Buckingham Strategic Partners Mersana Therapeutics, Inc. Transaction History
Buckingham Strategic Partners
- $6.15 Billion
- Q1 2025
A detailed history of Buckingham Strategic Partners transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Buckingham Strategic Partners holds 19,485 shares of MRSN stock, worth $7,209. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,485Holding current value
$7,209% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MRSN
# of Institutions
116Shares Held
101MCall Options Held
16.3KPut Options Held
13K-
Nextech Invest Ag12.1MShares$4.46 Million3.22% of portfolio
-
Nextech Invest, Ltd. Zurich, V812.1MShares$4.46 Million0.97% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$3.21 Million0.99% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$3.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.38MShares$3.1 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $36M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...